Director of the Retinoblastoma Program
Director of the Pediatric Oculoplastics service
Attending Physician
Professor of Clinical Ophthalmology, Keck School of Medicine of USC
  • Summary
  • Publications
  • Research
  • Media
  • Locations

Dr. Kim is carrying on the legacy established by Dr. Murphree to develop new treatment modalities to save the eyes of children with retinoblastoma and is actively engaged in new research translational research projects. Dr. Kim trained with Dr. David Abramson at MSKCC and was one of the first physicians in the US to treat retinoblastoma patients with intra-arterial chemotherapy in 2006. Dr. Kim was also one of the original co-authors of the seminal publication on selective intra-arterial chemotherapy for retinoblastoma in 2007. Dr. Kim and the rest of the Retinoblastoma team are dedicated to providing the best clinical care in the world to children afflicted with retinoblastoma.

Dr. Kim is also the Director of the Pediatric Oculoplastics service at CHLA, having trained with renowned surgeons Dr. Robert Goldberg, Dr. Norman Shorr and Dr. Henry Baylis at the Jules Stein Eye Institute in 2000. He provides surgical expertise in the common oculoplastic disorders such as blepharoptosis, tear duct obstructions and removal of benign and malignant orbital tumors. Dr. Kim is also one of the country’s experts in performing reconstructive surgery of the anophthalmic socket in retinoblastoma patients who have undergone enucleation. In 2018, he received the national James A. Katowitz award from the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) for excellence in pediatric ophthalmic surgery.

Clinical Interests

Ophthalmology, Pediatric Ocular Oncology, Retinoblastoma, Oculoplastic and orbital surgery

Education

Medical School: 

University of Iowa College of Medicine

Internship: 

Scripps Mercy Hospital

Residency: 

California Pacific Medical Center

Fellowship: 

Royal Liverpool University Hospital, Jules Stein Eye Institute of Los Angeles and Massachusetts Eye and Ear Infirmary

Accomplishments

Certification: 

Ophthalmology, American Board of Ophthalmology
Certified Member, American Society of Ophthalmic Plastic and Reconstructive Surgery

Awards: 

1994 Alpha Omega Alpha Medical Honor Society- College of Medicine, University of Iowa
1999 Heed Fellow- Heed Ophthalmic Foundation
2001 National Award for Outstanding Thesis- American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), Annual meeting, New Orleans
2007 Achievement Award- American Academy of Ophthalmology
2015 Senior Achievement Award- American Academy of Ophthalmology
2018 James A. Katowitz award for Excellence in Pediatric Ophthalmic Plastic and Recontructive Surgery- ASOPRS

Publications: 

Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. Case Report. A case series of NSCLS patients with different molecular characteristics and choroidal metastases. Improvement in vision with treatment including permetrexed and bevacizumab. J Thorac Oncol 2013 Feb;8(2):e17-8.

Berry JL, Astrahan M, Murphree AL, Lee TC, Kim JW. Outcomes of choroidal melanomas treated with Eye Physics plaques: 20 year review. JAMA Ophthalmol 131(11):1435-42, 2013.

Nugent AK*, Paulus YM*, Chan A*, Kim JW, Schwarts EJ, Moshfeghi D. Multiple myeloma recurrence with optic nerve infiltration diagnosed by vitrectomy, immunohistochemistry, and in-situ hybridization. Eur J Ophthalmol, Nov 11:0, 2013.

Ko M, Lad SP, Morris C, Kim JW, Lad NM. Orbital fractures: national inpatient trends and complications. Ophthalmic Plast Reconstr Surg, 29(4):298-303, 2013.

Berry JL, Jubran R, Murphree LM, Lee TC, Kim JW. Factors Predictive of Long-term Visual Outcomes of Group D Eyes Treated with Chemoreduction and Low-dose IMRT Salvage: The Children’s Hospital Los Angeles Experience. Br J Ophthalmol, Aug 98(8): 1061-5, 2014.

Kim JW, Ngai LK, Sadda S, Murakami Y, Lee TC, Murphree AL. Retcam fluorescein angiography findings in eyes with advanced retinoblastoma. Br J Ophthalmol 2014, Dec;98(12):1666-71.

Kim JW. Retinoblastoma: Evidence for postenucleation adjuvant chemotherapy. Int Ophthalmol Clin 2015 Winter; 55(1):77-96.

Berry JL, Jubran R, Murphree LM, Lee TC, Lee DK, Kim JW. Low-Dose Chemoreduction for infants diagnosed with retinoblastoma under 6 months of age. Ocul Oncol Pathol 2015; 1:103-110.

Browne A, Berry JL, Jennell R, Kim JW, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL. Outcomes of Medium Choroidal Melanomas Treated with Ruthenium Brachytherapy Guided by 3D Pretreatment Modeling. Brachytherapy, 04.010 Epub 2015 June 12.

Jacobsen B, Berry JL, Jubran R, Kim JW. Orbital recurrence following aggressive laser treatment for retinoblastoma, Ocul Oncol and pathol 2016; 2:76-79.

Zhu D,Berry JL, Kim JW, Jubran R. Long-term outcomes of Group B eyes in patients with retinoblastoma treated with short-course chemoreduction: experience from Children’s Hospital Los Angeles/University of Southern California. Ocul Oncol Pathol 2016;2;105-11.

Berry JB, Kim JW, Cobrinik D. Detections and intraretinal localization of an “invisible” retinoblastoma using optical coherence tomography. Ocul Oncol Pathol 2016:148-152.

Hong B, Say EA, Chevez-Barrios P, Lee TC, Kim JW. Anterior chamber cholesterolosis in a patient with retinoblastoma. Digit J Ophthalmol 2016 Mar 31;22(1):35-7.

Li WL, Buckley Sanchez-Lara P, Cobrinik D, Kim JW, Lee TC, Triche T. Sensitive and Comprehensive Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families. J Mol Diagn 2016 Jul;18(4):480-93.

Marvasti AH, Berry J, Saber MS, Kim JW, Huang AS. Anterior segment scleral fluorescein angiography in the evaluation of ciliary body neoplasm: two case reports. Case Rep Ophthalmol 2016;7:30-38. 

Ferrario A, Luna M, Rucker N, Wong W, Ledeman A, Kim JW, Gomer CJ. Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotropic tumors PLoS One 2016 April 6;11(4); e0153011..

Berry JL, Shih G, Moysidis SN, Jubran R, Wong K, Lee TC, Murphree AL, Kim JW. Patterns of subretinal fluid resolution in Group D retinoblastoma eyes treated with chemoreduction: experience from the Children’s Hospital Los Angeles/University of Southern California. Ophthalmic Genet 2016 Mar 2:1-4.

Berry JL, Kogachi K, Aziz HA. McGovern K, Zolfaghari E, Murphree AL, Jubran R, Kim JW.  Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatr Blood Cancer 2017 Apr;64(4). Epub 2016 Nov 5.

Aziz HA, Kim JW, Munier FL, Berry JL. Acute hemorrhagic retinopathy following intravireal melphalan injection for retinoblastoma: A report of two cases and technical modifications to enhance the prevention of retinal toxicity. Ocul Oncol Pathol 2017 Jan;3(1):34-40.

Berry JL, Anulao K, Kim JW. Optical coherence tomography imaging of a large spherical seed in retinoblastoma.. Ophthalmology 2017 Aug;124(8):1208.

Berry JL, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, Kim JW. Not all seeds are created equal:seed classification is predictive of outcomes in retinoblastoma. Ophthalmology 2017 Jun 24. Pii:s0161-6420(17)31225-3.

Berry JL. Shah S. Bechtold M. Zolfaghari E. Jubran R. Kim JW.  Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer 2017 Jun24 doi:10.1002/pbc.26696.

Amram AL. Rico G, Kim JW. Vitreous seeds in retinoblastoma: clinicopathologic classification and correlation. Chintagumpala M. Herzog CE, Gombos DS, Chevez-Barrios P. Ophthalmology 2017 May 17. Pii:S0161-6420(17)30285-3.

Mruthyunjaya P, Seider MI, Stinnett S, Schefler A; Ocular oncology study Consortium. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma Ophthalmology 2017 May 23 pii:S0161-6420(16)31873-5.

Kim JW, Jacobsen BH, Ko M, Lee DK, Jubran RF, Berry JL. Three presentations of CNS disease in patients with intraocular retinoblastoma at a tertiary medical center in the United States. Ophthalmic Genet 2017 Sept 26:1-5.

Wang LC, Kim JW, Rao NA. Coexisting phacoanaphylaxis and choroidal melanoma: An unusual intraocular inflammation. Ocul immunol inflamm 2017;00(00)1-5. 

Kim JW, Jacobsen B, Zolfaghari E, et al. Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft. Graef Arch Clin Exp Ophthalmol 2017, (s00417-017), 3805-8.

Berry JL, Xy L, Murphree AL, Krishnan S, Stachelek K, Xolfaghari E, McGovern K, Lee TC, Carlsson A, Kuhn P, Kim JW, Cobrinik D, Hicks J. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. JAMA Ophthalmol 2017, nov 1;135(11):1221-1230.

Berry JL, Zolfaghari E, Chen A, Murphree AL, Jubran R, Kim JW. Optic Nerve Obscuration in Retinoblastoma: A Risk Factor for Optic Nerve Invasion? Ocul Oncol Pathol 2017 Nov;3(4):283-291.

Szymaski LJ, Sibug Saber MR, Kim JW, Go JL, Zada G, Rao N, Hurth KM. Quadruple Neoplasms following Radiation Therapy for Congenital Bilateral Retinoblastoma. Ocul Oncol Pathol 2017 Dec;4(1):33-37.

Zolfaghari E, Kim JW, Krishnan S, Chevez-Barrios P, Berry JL. Atypical Retinal Pigment Epithelial Hyperplasia and Glial Proliferation Masquerading as Progressive Recurrent Retinoblastoma: A Case Report Review and Clinicopathologic Correlation. Ocul Oncol Pathol 2018 Sep 4(2):116-121.

Skalet AH, Gombos DS, Gallie BL, Kim JW, Shields CL, Marr BP, Plan SE, Chevez-Barrios P. Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. Ophthalmology 2018 Mar;125(3):453-458. 

Shah S, Koban Y, Le BHA, Bechtold M, Zolfaghari E, Kim JW, Berry JL. Iris Hypoplasia as the presenting Sign of Retinoblastoma in a Child With a 13q Deletion. J Pediatric Ophthalmol Strabismus 2018 Apr 23;55:e10-e13.

Berry JL, Kogachi K, Jubran R, Kim JW. Loss of fundus view as an indication for secondary enucleation in retinoblastoma. Pediatr Blood Cancer. 2018 Apr; 65(4).

Berry JL, Lewis L, Zolgahgari E, Green S, Le BHA, Lee TC, Murphree AL, Kim JW, Jubran R. Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing. Ophthalmic Genet 2018 Jun;39 (3):407-409.

Lang P, Kim JW, McGovern K, Reid MW, Subramanian K, Murphree AL, Berry JL. Porous orbital implant after enucleation in retinoblastoma patients: indications and complications. Orbit 2018 Feb 20:1-6.

Berry JL, Xu L, Kooi I, Murphree AL, Prabakar RK, Reid MW, Stachelek K, Le BHA, Welter L, Reiser BJ, Chevez-Barrios P, Jubran R, Lee TC, Kim JW, Kuhn P, Cobrink D, Hicks J. Genomic cfDNA Analysis of Aqueous Humor in Retinoblastoma Predicts Eye Salvage: The Surrogate Tumor Biopsy for Retinoblastoma. Mol Cancer Res 2018 Jul 30, 0369.2018. doi: [Epub ahead of print].

 Le BHA, Kim JW, Deng H, Rayess N, Jennelle RL, Zhou SY, Astrahan MA, Berry JL. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review. Brachytherapy 2018 Aug 3. S1538-4721(18)30108-9. (Epub ahead of print).

Polski A, Sibug Saber M, Kim JW, Berry JL. Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia. Clin Exp Ophthalmol 2018 Aug 29 (Epub ahead of print).

Kogachi K, Kim JW, Green S, Jubran R, Berry JL. Lurking below: massive choroidal invasion under a calcified tumor after attempted conservative therapy for retinoblastoma. Ophthalmic Genet 2018 Aug 24:1-5 (Epub ahead of print).

Nguyen SM, Sison J, Jones M, Berry JL, Kim JW, Murphree AL, Salinas V, Olch AJ, Chang EL, Wong KK. Lens dose-response prediction modeling and cataract incidence in retinoblastoma patients after lens-sparing or whole-eye radiotherapy. Int J Radat Oncol Biol Phys 2018 Dec 8. (18);34083-5.

Berry JL, Shah S, Kim F, Jubran R, Kim JW. Integrated treatment during the intravitreal melphalan era: concurrent intravitreal melphalan and systemic chemoreduction Ocul Oncol Pathol 2018 Nov;4(6):335-340.

Research Interests: 

Research Topics

  • Retinoblastoma

  • Targeted eye therapies

Research Overview

Retinoblastoma is a very rare cancer that develops in the eyes of young children, affecting one in 18,000 babies in the United States. Although rare, retinoblastoma is devastating when it occurs, since in the majority of cases there is no family history and therefore no warning. Although there are many effective therapies available to treat retinoblastoma, we face many challenges in trying to save the vision and the lives of affected children. Retinoblastoma develops in the retina of the developing eye due to a specific mutation in a gene on chromosome 13. With proper diagnosis and treatment, spread outside the eye is fortunately rare, but many children lose their vision and sometimes the eye itself. 

From an epidemiologic standpoint, there are many challenges to preventing retinoblastoma. In most children, the cancer develops from a random, rare mutation that cannot be predicted based on any historical or clinical factors. Typically, the diagnosis cannot be made until the tumor becomes quite large and causes signs such as leukocoria (white pupil reflex) or strabismus. Therefore, even well-trained pediatricians are not able to diagnose retinoblastoma at an early stage since there are no external signs of abnormalities and vision in pre-verbal children cannot be accurately measured.

As the Director of the Retinoblastoma service, my role is to provide the full spectrum of clinical services when a child is diagnosed with retinoblastoma. I follow the child from the time of diagnosis to the end of their treatment course as adults. At Children's Hospital Los Angeles, we offer all of the treatments available in the world, including laser photocoagulation, systemic, regional and ocular chemotherapy as well as brachytherapy and external beam radiation treatment.

Our main research mission is to develop targeted therapies for retinoblastoma that will kill cancer cells while sparing other normal cells. Unlike traditional therapies such as chemotherapy and radiation, targeted therapies have the potential to achieve cancer cures while minimizing side effects. To accomplish this goal, we need partnerships between experts in different fields, from cell biologists to radiation oncologists to hematology oncologists. We also need collaboration between clinicians and basic science researchers at The Saban Research Institute. The basic paradigm for developing a new therapy starts with an idea based on a clinical need, followed by development of a research strategy based on basic research principles. We may test the therapy on retinoblastoma cells in a test tube (in vitro), followed by an animal model (in vivo). If promising results are achieved, then a limited clinical trial on carefully selected patients may follow. Translational research is the key to achieving progress in this field, and we are committed to developing new therapies to improve clinical outcomes in our children with retinoblastoma. 

Visit the Jonathan Kim Laboratory.

In The News - Press Releases

4650 Sunset Blvd.
MS #88
Los Angeles, CA 90027
Phone: 323-361-6275Office
Fax: 323-361-3512Fax